{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T17:55:59Z","timestamp":1774115759683,"version":"3.50.1"},"reference-count":32,"publisher":"Pharmaceutical Society of Japan","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological & Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2015]]},"DOI":"10.1248\/bpb.b14-00652","type":"journal-article","created":{"date-parts":[[2015,1,7]],"date-time":"2015-01-07T22:05:25Z","timestamp":1420668325000},"page":"411-416","source":"Crossref","is-referenced-by-count":6,"title":["Comparative Study of the Anti-leukemic Effects of Imatinib Mesylate, Glivec\u2122 Tablet and Its Generic Formulation, OHK9511"],"prefix":"10.1248","volume":"38","author":[{"given":"Masako","family":"Yokoo","sequence":"first","affiliation":[{"name":"Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Kubota","sequence":"additional","affiliation":[{"name":"Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University"},{"name":"Department of Transfusion Medicine, Saga University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoko","family":"Tabe","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory Medicine, Juntendo University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Kimura","sequence":"additional","affiliation":[{"name":"Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Mitra D, Trask PC, Iyer S, Candrilli SD, Kaye J. Patient characteristics and treatment patterns in chronic myeloid leukemia: evidence from a multi-country retrospective medical record chart review study. Int. J. Hematol.<\/i>, 95<\/b>, 263\u2013273 (2012).","DOI":"10.1007\/s12185-012-1010-4"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Rohon P. Biological therapy and the immune system in patients with chronic myeloid leukemia. Int. J. Hematol.<\/i>, 96<\/b>, 1\u20139 (2012).","DOI":"10.1007\/s12185-012-1116-8"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Gambacorti-Passerini C, Antolini L, Mahon FX, Guilhot F, Deininger M, Fava C, Nagler A, Della Casa CM, Morra E, Abruzzese E, D'Emilio A, Stagno F, le Coutre P, Hurtado-Monroy R, Santini V, Martino B, Pane F, Piccin A, Giraldo P, Assouline S, Durosinmi MA, Leeksma O, Pogliani EM, Puttini M, Jang E, Reiffers J, Valsecchi MG, Kim DW. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J. Natl. Cancer Inst.<\/i>, 103<\/b>, 553\u2013561 (2011).","DOI":"10.1093\/jnci\/djr060"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med.<\/i>, 344<\/b>, 1031\u20131037 (2001).","DOI":"10.1056\/NEJM200104053441401"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Smith TJ, Hillner BE. Bending the cost curve in cancer care. N. Engl. J. Med.<\/i>, 364<\/b>, 2060\u20132065 (2011).","DOI":"10.1056\/NEJMsb1013826"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Noens L, van Lierde MA, De Bock R, Verhoef G, Zachee P, Berneman Z, Martiat P, Mineur P, Van Eygen K, MacDonald K, De Geest S, Albrecht T, Abraham I. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood<\/i>, 113<\/b>, 5401\u20135411 (2009).","DOI":"10.1182\/blood-2008-12-196543"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Wu EQ, Johnson S, Beaulieu N, Arana M, Bollu V, Guo A, Coombs J, Feng W, Cortes J. Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients. Curr. Med. Res. Opin.<\/i>, 26<\/b>, 61\u201369 (2010).","DOI":"10.1185\/03007990903396469"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Dusetzina SB, Winn AN, Abel GA, Huskamp HA, Keating NL. Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia. J. Clin. Oncol.<\/i>, 32<\/b>, 306\u2013311 (2014).","DOI":"10.1200\/JCO.2013.52.9123"},{"key":"9","unstructured":"9) Ricci C, Scappini B, Divoky V, Gatto S, Onida F, Verstovsek S, Kantarjian HM, Beran M. Mutation in the ATP-binding pocket of the ABL kinase domain in an STI571-resistant BCR\/ABL-positive cell line. Cancer Res.<\/i>, 62<\/b>, 5995\u20135998 (2002)."},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Ito T, Tanaka H, Kimura A. Establishment and characterization of a novel imatinib-sensitive chronic myeloid leukemia cell line MYL, and an imatinib-resistant subline MYL-R showing overexpression of Lyn. Eur. J. Haematol.<\/i>, 78<\/b>, 417\u2013431 (2007).","DOI":"10.1111\/j.1600-0609.2007.00835.x"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Kimura S, Naito H, Segawa H, Kuroda J, Yuasa T, Sato K, Yokota A, Kamitsuji Y, Kawata E, Ashihara E, Nakaya Y, Naruoka H, Wakayama T, Nasu K, Asaki T, Niwa T, Hirabayashi K, Maekawa T. NS-187, a potent and selective dual Bcr-Abl\/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia. Blood<\/i>, 106<\/b>, 3948\u20133954 (2005).","DOI":"10.1182\/blood-2005-06-2209"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Kimura S, Kuroda J, Segawa H, Sato K, Nogawa M, Yuasa T, Ottmann OG, Maekawa T. Antiproliferative efficacy of the third-generation bisphosphonate, zoledronic acid, combined with other anticancer drugs in leukemic cell lines. Int. J. Hematol.<\/i>, 79<\/b>, 37\u201343 (2004).","DOI":"10.1007\/BF02983531"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Jin L, Tabe Y, Kimura S, Zhou Y, Kuroda J, Asou H, Inaba T, Konopleva M, Andreeff M, Miida T. Antiproliferative and proapoptotic activity of GUT-70 mediated through potent inhibition of Hsp90 in mantle cell lymphoma. Br. J. Cancer<\/i>, 104<\/b>, 91\u2013100 (2011).","DOI":"10.1038\/sj.bjc.6606007"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Tabe Y, Konopleva M, Munsell MF, Marini FC, Zompetta C, McQueen T, Tsao T, Zhao S, Pierce S, Igari J, Estey EH, Andreeff M. PML-RAR\u03b1 is associated with leptin-receptor induction: the role of mesenchymal stem cell-derived adipocytes in APL cell survival. Blood<\/i>, 103<\/b>, 1815\u20131822 (2004).","DOI":"10.1182\/blood-2003-03-0802"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Naito H, Kimura S, Nakaya Y, Naruoka H, Kimura S, Ito S, Wakayama T, Maekawa T, Hirabayashi K. In vivo<\/i> antiproliferative effect of NS-187, a dual Bcr-Abl\/Lyn tyrosine kinase inhibitor, on leukemic cells harbouring Abl kinase domain mutations. Leuk. Res.<\/i>, 30<\/b>, 1443\u20131446 (2006).","DOI":"10.1016\/j.leukres.2006.01.006"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Kuroda J, Kimura S, Segawa H, Kobayashi Y, Yoshikawa T, Urasaki Y, Ueda T, Enjo F, Tokuda H, Ottmann OG, Maekawa T. The third-generation bisphosphonate zoledronate synergistically augments the anti-Ph+ leukemia activity of imatinib mesylate. Blood<\/i>, 102<\/b>, 2229\u20132235 (2003).","DOI":"10.1182\/blood-2003-01-0305"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Hahn EA, Glendenning GA, Sorensen MV, Hudgens SA, Druker BJ, Guilhot F, Larson RA, O\u2019Brien SG, Dobrez DG, Hensley ML, Cella D, IRIS Investigators. Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus<\/i> interferon alfa plus low-dose cytarabine: results from the IRIS Study. J. Clin. Oncol.<\/i>, 21<\/b>, 2138\u20132146 (2003).","DOI":"10.1200\/JCO.2003.12.154"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Baccarani M, Druker BJ, Branford S, Kim DW, Pane F, Mongay L, Mone M, Ortmann CE, Kantarjian HM, Radich JP, Hughes TP, Cortes JE, Guilhot F. Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) study. Int. J. Hematol.<\/i>, 99<\/b>, 616\u2013624 (2014).","DOI":"10.1007\/s12185-014-1566-2"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Marin D, Bazeos A, Mahon FX, Eliasson L, Milojkovic D, Bua M, Apperley JF, Szydlo R, Desai R, Kozlowski K, Paliompeis C, Latham V, Foroni L, Molimard M, Reid A, Rezvani K, de Lavallade H, Guallar C, Goldman J, Khorashad JS. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J. Clin. Oncol.<\/i>, 28<\/b>, 2381\u20132388 (2010).","DOI":"10.1200\/JCO.2009.26.3087"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Ibrahim AR, Eliasson L, Apperley JF, Milojkovic D, Bua M, Szydlo R, Mahon FX, Kozlowski K, Paliompeis C, Foroni L, Khorashad JS, Bazeos A, Molimard M, Reid A, Rezvani K, Gerrard G, Goldman J, Marin D. Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. Blood<\/i>, 117<\/b>, 3733\u20133736 (2011).","DOI":"10.1182\/blood-2010-10-309807"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Kodama Y, Morozumi R, Matsumura T, Kishi Y, Murashige N, Tanaka Y, Takita M, Hatanaka N, Kusumi E, Kami M, Matsui A. Increased financial burden among patients with chronic myelogenous leukaemia receiving imatinib in Japan: a retrospective survey. BMC Cancer<\/i>, 12<\/b>, 152\u2013161 (2012).","DOI":"10.1186\/1471-2407-12-152"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Widmer N, Bardin C, Chatelut E, Paci A, Beijnen J, Leveque D, Veal G, Astier A. Review of therapeutic drug monitoring of anticancer drugs. Part two\u2014targeted therapies. Eur. J. Cancer<\/i>, 50<\/b>, 2020\u20132036 (2014).","DOI":"10.1016\/j.ejca.2014.04.015"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Goubran HA. Failure of a non-authorized copy product to maintain response achieved with imatinib in a patient with chronic phase chronic myeloid leukemia: a case report. J. Med. Case. Rep.<\/i>, 3<\/b>, 7112\u20137114 (2009).","DOI":"10.1186\/1752-1947-3-7112"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Asfour IA, Elshazly SA. Changing therapy from Glivecto a \u201ccopy\u201d imatinib results in a worsening of chronic myeloid leukemia disease status: two case reports. Cases. J.<\/i>, 2<\/b>, 9342\u20139345 (2009).","DOI":"10.1186\/1757-1626-2-9342"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Chouffai Z. Hematologic relapse after 2 years on a non-authorized copy version of imatinib in a patient with chronic myeloid leukemia in chronic phase: a case report. Case. Rep. Oncol<\/i>, 3<\/b>, 272\u2013276 (2010).","DOI":"10.1159\/000319150"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Mattar M. Failure of copy Imatib (CIPLA, India) to maintain hematologic and cytogenetic responses in chronic myeloid leukemia in chronic phase. Int. J. Hematol.<\/i>, 91<\/b>, 104\u2013106 (2010).","DOI":"10.1007\/s12185-009-0431-1"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Gogtay J, Chahchad S, Jadhav S, Purandare S. Response to the case report by Mattar: Generic Imatinib (Imatib, Cipla) in a patient with chronic myeloid leukemia in chronic phase. Int. J. Hematol.<\/i>, 92<\/b>, 772\u2013773 (2010).","DOI":"10.1007\/s12185-010-0718-2"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Eskazan AE, Elverdi T, Yalniz FF, Salihoglu A, Ar MC, Ongoren Aydin S, Baslar Z, Aydin Y, Tuzuner N, Ozbek U, Soysal T. The efficacy of generic formulations of imatinib mesylate in the treatment of chronic myeloid leukemia. Leuk. Lymphoma<\/i>, 55<\/b>, 2935\u20132937 (2014).","DOI":"10.3109\/10428194.2014.905774"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Eskazan AE, Ayer M, Kantarcioglu B, Arica D, Demirel N, Aydin D, Yalniz FF, Elverdi T, Salihoglu A, Ar MC, Ongoren Aydin S, Baslar Z, Aydin Y, Tuzuner N, Ozbek U, Soysal T. First line treatment of chronic phase chronic myeloid leukaemia patients with the generic formulations of imatinib mesylate. Br. J. Haematol.<\/i>, 167<\/b>, 139\u2013141 (2014).","DOI":"10.1111\/bjh.12937"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Picard S, Titier K, Etienne G, Teilhet E, Ducint D, Bernard MA, Lassalle R, Marit G, Reiffers J, Begaud B, Moore N, Molimard M, Mahon FX. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood<\/i>, 109<\/b>, 3496\u20133499 (2007).","DOI":"10.1182\/blood-2006-07-036012"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Singh N, Kumar L, Meena R, Velpandian T. Drug monitoring of imatinib levels in patients undergoing therapy for chronic myeloid leukaemia: comparing plasma levels of responders and non-responders. Eur. J. Clin. Pharmacol.<\/i>, 65<\/b>, 545\u2013549 (2009).","DOI":"10.1007\/s00228-009-0621-z"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Larson RA, Druker BJ, Guilhot F, O\u2019Brien SG, Riviere GJ, Krahnke T, Gathmann I, Wang Y, IRIS Study Group. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood<\/i>, 111<\/b>, 4022\u20134028 (2008).","DOI":"10.1182\/blood-2007-10-116475"}],"container-title":["Biological & Pharmaceutical Bulletin","Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/38\/3\/38_b14-00652\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,19]],"date-time":"2019-08-19T11:23:44Z","timestamp":1566213824000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/38\/3\/38_b14-00652\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b14-00652","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015]]}}}